JDP, RAC must know all this.
But IIRC RAC has never mentioned that FTO inhibition significantly decreases HCM viability when dosed with cardiotoxic agents.
To do so would provoke discussion about Zan's CP MOA, which is a taboo subject.
Cardioprotection thread, page-495
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.87 |
Change
-0.025(1.32%) |
Mkt cap ! $317.5M | |||
| Open | High | Low | Value | Volume |
| $1.97 | $2.02 | $1.85 | $1.189M | 605.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.86 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.89 | 30 | 1 |
View Market Depth
| Last trade - 16.10pm 13/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.86 |
Change
-0.025 ( 1.00 %) |
||||
| Open | High | Low | Volume | ||
| $1.97 | $2.04 | $1.86 | 48029 | ||
| Last updated 15.57pm 13/06/2024 ? | |||||
| RAC (ASX) Chart |